Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister

Chris Bryant says reduction of government support was linked to change in drugmaker’s proposed investment

The Guardian - UK

AstraZeneca investment deal ‘didn’t add up for UK taxpayer’, says minister

Science minister Sir Chris Bryant said the Government feels regretful about the plan being ditched and ‘would prefer to have got this over the line’.

Evening Standard

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

What the papers say – February 1

Here are the major stories grabbing the attention on Saturday’s news stands.

Evening Standard

What has the UK Covid inquiry learned so far about vaccines and treatments?

In fourth part of the inquiry, questons were asked about vaccine trials, procurement and the UK’s preparedness for future pandemics

The Guardian - UK

Fresh blow for Rachel Reeves as AstraZeneca scraps £450m investment in UK vaccine plant

The pharmaceutical giant claimed the Labour Government failed to match its predecessor’s offer but the cancelled project is a blow to the chancellor’s growth agenda

The Independent UK

AstraZeneca cancels £450m vaccine plant in UK after Government 'own goal' in blow to Rachel Reeves growth plan

The pharmaceutical giant claimed the Labour Government failed to match Tory predecessor’s offer of help for its investment in Merseyside

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca axes £450m vaccine plant in Liverpool, blaming state funding cut

Days after Rachel Reeves highlighted life sciences as UK strength, firm decides against site expansion

The Guardian - UK

Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket

This biotech stock is a promising buy, but it does come with risks.

Barchart

Daily pill on NHS offers new hope for hundreds with lung cancer

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery

The Independent UK

Well-known medics to appear in front of UK Covid probe

Module four of the inquiry is looking at the development and rollout of vaccines in the UK.

The Independent UK

GSK to buy US cancer drug firm IDRx for up to $1.15bn

Massachusetts-based company is working on new treatments for gastrointestinal cancers

The Guardian - UK

From the Beatles to biologics – how Liverpool became a life science hotspot

The city has a long history with tropical medicine and is now home to one of the largest biotech clusters in Europe

The Guardian - UK

Breast cancer drug Lynparza reduces risk of death by 28% in patients diagnosed early, clinical trial shows

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

Top News

Astrazeneca Appoints New China Head Amid Investigation Concerns

AstraZeneca appoints Iskra Reic as new head of China operations amid investigations and challenges in the pharmaceutical industry in China.

The Conversation

First new treatment for asthma and COPD in half a century – new study

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially life-threatening episodes has remained unchanged – treatment with steroids, such as prednisolone.

MarketBeat

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca's Truqap Demonstrates Progress in Advanced Prostate Cancer Treatment

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically

The Guardian - UK

Breast cancer drug blocked for NHS use in England and Wales after talks collapse

National Institute for Health and Care Excellence unable to reach price agreement with manufacturers of Enhertu

Evening Standard

Breast cancer drug blocked for NHS use as price talks break down for third time

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.

The Independent UK

Breast cancer drug blocked for NHS use as price talks break down – leaving charities ‘beyond devastated’

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu

The Guardian - UK

Pharma shares hit as Trump picks RFK Jr to lead health department

Choice of vaccine critic knocks some of world’s biggest drugmakers including Moderna, AstraZeneca and GSK

The Guardian - UK

AstraZeneca’s numbers are good but trouble in China could drag it down

Profits beat forecasts but a 17% fall in share price since executives were detained by Beijing may be hard to shake

The Guardian - UK

AstraZeneca says it takes China investigation ‘very seriously’

UK’s biggest pharmaceutical company ‘committed to China’ as it raises 2024 profit forecast and announces $3.5bn US investment

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.